Cognition Therapeutics Announces Dosing of First Alzheimer's Patient in Phase 1b Trial of CT1812

PITTSBURGH, Nov. 11, 2016 /PRNewswire/ -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer's disease and other neurocognitive disorders, announced today that the first Alzheimer's patient has been dosed in a Phase 1b clinical trial of CT1812 in mild to moderate Alzheimer's disease.

CT1812 is a first-in-class, orally available, small molecule that displaces bound Aβ oligomers and inhibits binding of Aβ oligomers to the receptor complex. By targeting and displacing these toxic beta amyloid oligomers, CT1812 has been shown in disease models of Alzheimer's disease to stop and reverse memory loss. In Phase 1a clinical studies, CT1812 was found to be safe when administered at multiple dose levels using a once daily oral dosing schedule for up to two weeks.

The newly initiated Phase 1b clinical trial will study CT1812 dosed daily for 28 days in individuals with mild to moderate Alzheimer's disease.  Patients will be randomized to one of two doses of CT1812 (280mg or 560mg) or placebo. The Phase 1b study is designed to help evaluate the safety, tolerability and pharmacokinetic profile of CT1812.  It will also help establish the recommended dose of CT1812 for a larger Phase 2 study in patients with mild to moderate Alzheimer's disease.  Data from this Phase 1b study are expected in mid-2017.

"Evidence suggests that CT1812 has the potential to rapidly reverse the memory loss seen in Alzheimer's disease and to stop disease progression," said Susan Catalano, PhD., Cognition Therapeutics' Chief Scientific Officer and Founder.  "CT1812's novel mechanism of action as the first orally active drug that displaces beta amyloid oligomers represents a potentially major therapeutic advance for the millions of individuals suffering from Alzheimer's disease."

"The dosing of patients with Alzheimer's disease is a major milestone for Cognition and CT1812," said Kenneth I. Moch, President and CEO of Cognition Therapeutics. "We are pleased by the pace of CT1812's clinical program and remain on track to initiate additional trials in 2017 which will further demonstrate the therapeutic potential of CT1812."

About CT1812

CT1812 is a proprietary first-in-class, orally available small molecule that displaces bound beta amyloid oligomers and inhibits binding of Aβ oligomers to the receptor complex. The molecule was designed by Cognition's scientific team, led by Susan Catalano, Ph.D., to target and displace the toxic beta amyloid oligomers that cause Alzheimer's disease. CT1812 has been shown in multiple Alzheimer's disease models to reverse memory loss. 

In the Phase 1b Study COG0102, patients with mild to moderate Alzheimer's disease will be randomized to one of two doses of CT1812 (280mg patients or 560mg) or placebo, and dosed for 28 days to help evaluate the safety, tolerability and pharmacokinetic profile of CT1812. Cognition has previously conducted Phase 1a single and multiple ascending dose studies in 94 healthy volunteers, 74 of whom received CT1812.  StudyCOG0102 is supported in part under Award Number RF1AG054176 from the National Institute on Aging of the National Institutes of Health.

About Cognition Therapeutics, Inc.

Cognition Therapeutics (CogRx) is a privately held biopharmaceutical company whose disease-relevant screening and novel chemistry platforms have produced a pipeline of disease modifying small molecule drug candidates which are being developed to treat Alzheimer's disease and potentially other neurocognitive disorders. CogRx's lead clinical stage drug candidate, CT1812, currently in Phase 1b clinical testing, has shown the ability to restore memory to normal in Alzheimer's disease models.  Additional information about Cognition may be found online at http://www.cogrx.com.

Forward-Looking Statements

This press release contains "forward-looking statements" concerning the development and commercialization of CogRx's products, the potential benefits and attributes of such products, and CogRx's expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. CogRx undertakes no obligation to update any forward-looking statements for any reason.

CONTACT:
Diane Pearson
[email protected]
(412) 626-7670

Logo - http://photos.prnewswire.com/prnh/20161027/433571LOGO

SOURCE Cognition Therapeutics, Inc.

Related Links

http://www.cogrx.com